Retrospective Evaluation of LDL-C Levels Following First Treatment With Inclisiran as Part of Secondary Prevention ASCVD Risk Reduction in a Real-World Primary Care Setting

Introduction: Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of death and disability worldwide. There is a direct relationship between increasing levels of LDL-C and increased risk of ASCVD. Guidance from the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) recommends that high-risk ASCVD patients maintain an LDL-C <1.8 mmol/L (70 mg/dL) and very high-risk patients <1.4 mmol/L (55 mg/dL). National data in England reveals that 71% of high-risk secondary prevention patients have an LDL-C >1.8 mmol/L (70 mg/dL). Methodology: An ASCVD risk reduction approach was initiated in a primary care clinic in December 2021. Of those patients who underwent review between December 2021 and July 2023, 102 patients were started on inclisiran treatment in a real-world setting. These patients were retrospectively reviewed to determine the initial effects of using inclisiran after the first dose as part of the patients’ ASCVD risk reduction management. Results: After 1 injection of Inclisiran, the patients’ mean decrease in LDL-C was 2.00 mmol/L (77.3 mg/dL) after a mean of 87 days. This represented a mean reduction of 61.7% (SD = 19.8) in their LDL-C measurements. The addition of inclisiran resulted in 79.4% of patients achieving an LDL-C target of <1.8 mmol/L (70 mg/dL) and 65.7% of patients attaining an LDL-C of <1.4 mmol/L (55 mg/dL). Conclusion: Healthcare providers working in primary care can achieve recommended LDL-C targets in 4 out of 5 secondary prevention patients after an initial dose of inclisiran as part of their ASCVD risk reduction approach management.